Surprising longevity boosters: top medications revealed

You might have been increasing your lifespan without even knowing it. Have you been taking Viagra or Estradiol? At least these are the results of European scientists’ major retrospective study. Read Hot Science below.

Investors are flocking to CAR-T-related therapeutics companies. The promise of lower risk and incredible return on investments is the reason. Read Hot Investments below.

‍

Hot Science

European researchers have examined the association of the top 406 prescribed medications with overall mortality rates within the general population of the UK. The study utilized the extensive UK biobank registry containing de-identified information from half a million UK participants. As expected, most prescription drugs are linked to increased mortality—likely due to the underlying conditions they treat or their side effects. However, the researchers discovered that use of 14 drugs correlates, to a different degree, with decreased mortality rates. They specifically noted four drugs that are among the best longevity “winners”: Sildenafil (Viagra), Atorvastatin, Naproxen and Estradiol.

While those types of studies are important contributions to understanding the aging phenotype, some longevity focused companies aim to target diseases of aging at a more robust level. For instance, Immorta Bio focuses on cell rejuvenation and senotherapeutics and develops personalized therapeutic interventions that could potentially offer more effective solutions.‍

‍

Hot Investments

CAR-T technologies have catapulted multiple companies to prominence and provided hefty returns to the investors. Capstan Therapeutics has joined the trend with an impressive $175 million fundraising success. Focusing on pioneering CAR-T cell therapies by leveraging messenger RNA, Capstan has made significant strides, especially with their flagship program CPTX2309. It aims to treat autoimmune diseases by using mRNA to guide T cells against CD19-positive cells. While co-founder Carl June, a notable figure in CAR-T research, highlighted some challenges of this innovative approach, the investors are obviously convinced the program will be successful.

Combination therapies, that include CAR-T, are multiplying. Immorta Bio has introduced senotherapeutics program SECL-31 potentially opening a new chapter in spreading CAR-T hematological diseases success to solid tumors. ‍

‍

Longevity Shorts

• Study finds higher dietary flavanol intake linked to reduced all-cause, cancer, and cardiovascular mortality risks among U.S. adults.  
  

• The Live Long Summit in West Palm Beach brought together leading experts in longevity to explore cutting-edge strategies for extending human lifespan and enhancing health.

• Immorta Bio intellectual property portfolio has grown to 12 patents, including such foundational ones, as their Personalized Progenitor Cell (PPC) platform, patent application #63/599440.

‍

Term of the Day

What is Scientific Longevity?​

We call Scientific  Longevity science-based and regulatory proven research and development of therapeutics that extend lives while improving health.

‍

Boris Reznik, PhD
Chairman

‍